World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Duke's contributions to improving survival rates and quality of life for brain tumor patients

Chidinma Madu [1,*] and Ajibade Victoria Mofiyinfoluwa [2]

[1] *Department of Neuro-Oncology, Duke Health Systems, USA,*
[2] *Department of Critical Care Registered Nurse, Duke Health Systems, USA.*

World Journal of Biology Pharmacy and Health Sciences, 2025, 22(02), 342-351

Publication history: Received on 30 March 2025; revised on 14 May 2025; accepted on 17 May 2025

Article DOI: https://doi.org/10.30574/wjbphs.2025.22.2.0482

Abstract

Background: Duke University has been at the forefront of advancing treatments for brain tumor patients, significantly improving survival rates and quality of life. Through pioneering research in immunotherapy, including the development of the poliovirus-based therapy *(PVSRIPO)*, Duke has shown promising results in combating glioblastoma. Their cutting-edge neurosurgical techniques and precision medicine approaches have enhanced treatment efficacy while minimizing side effects. Additionally, Duke's comprehensive brain tumor center offers multidisciplinary care, integrating innovative therapies with patient-centered support. Ongoing clinical trials continue to push the boundaries of brain tumor treatment, offering hope to patients worldwide.

Aim: The aim of this study is to analyze Duke's contributions to improving survival rates and quality of life for brain tumor patients through innovative research, advanced treatment strategies, and comprehensive patient care. This includes evaluating the impact of Duke's breakthroughs in immunotherapy, precision medicine, and neurosurgical techniques, as well as the role of its multidisciplinary approach in enhancing patient outcomes.

Methods: Duke has made significant contributions to improving survival rates and quality of life for brain tumor patients through groundbreaking research and innovative treatments. Their advancements in immunotherapy, such as the poliovirus therapy for glioblastoma, have shown promising results. Duke's specialized brain tumor center offers cutting-edge surgical techniques and personalized treatment plans. They focus on holistic patient care, integrating rehabilitation and supportive therapies to enhance quality of life. Clinical trials at Duke provide access to novel therapies, giving patients new hope and improved outcomes.

Plain language summary: Duke has made major strides in improving survival rates and quality of life for brain tumor patients. Through cutting-edge research, innovative therapies, and clinical trials, they have developed more effective treatments. Their patient-centered approach ensures comprehensive, compassionate care. Advanced surgical techniques and precision medicine have enhanced outcomes. Duke continues to lead in transforming brain tumor treatment and patient well-being.

Result: Duke has made major strides in improving survival rates and quality of life for brain tumor patients. Through cutting-edge research, innovative therapies, and clinical trials, they have developed more effective treatments. Their patient-centered approach ensures comprehensive, compassionate care. Advanced surgical techniques and precision medicine have enhanced outcomes. Duke continues to lead in transforming brain tumor treatment and patient well-being.

* Corresponding author: Chidinma Madu

Duke University has been a game-changer in the world of brain tumor research, treatment, and patient care, making a real difference in survival rates and overall quality of life. With its cutting-edge clinical trials, innovative surgical methods, and groundbreaking immunotherapy strategies, Duke's Preston Robert Tisch Brain Tumor Center has earned its reputation as a global leader in neuro-oncology. The center has been instrumental in developing targeted therapies, like the use of poliovirus-based immunotherapy for glioblastoma, which has shown great promise in improving survival rates. Plus, advancements in precision medicine, such as genomic profiling and molecular-targeted treatments have paved the way for more personalized and effective care. Duke takes a team-based approach, bringing together experts in neurosurgery, brain tumor, and supportive care to create treatment plans that maximize effectiveness while minimizing side effects. The introduction of minimally invasive surgical techniques and state-of-the-art imaging technologies has made tumor removal more precise, leading to fewer complications and quicker recoveries for patients. On top of that, Duke has been at the forefront of research into new chemotherapy delivery methods, like convection-enhanced drug delivery, which allows for direct drug administration to tumors while bypassing the blood-brain barrier. But it's not just about medical treatments at Duke; they're also dedicated to enhancing patients' quality of life through rehabilitation programs, palliative care, and mental health support. Their research into cognitive rehabilitation, lifestyle changes, and survivorship programs ensures that patients receive comprehensive care that addresses both their physical and emotional needs. Moreover, Duke's impact on brain tumor research goes beyond the lab, as they actively engage in advocacy and education to raise awareness and shape healthcare policies that benefit patients around the globe.

Keywords: Duke University; Brain tumor; Brain tumor; Patient care

1. Introduction

An Overview of Brain Tumors and Their Impact on Patients. Brain tumors are some of the most intricate and life-changing medical issues, impacting thousands of individuals around the globe each year. These tumors arise from abnormal cell growth in the brain or its surrounding areas, leading to serious health complications. They fall into two main categories: primary brain tumors, which start in the brain itself, and secondary (metastatic) brain tumors, which spread from cancers that originate elsewhere in the body. Within these categories, brain tumors can be benign (non-cancerous) or malignant (cancerous), with malignant tumors posing a greater threat to survival and overall well-being. One of the most prevalent and aggressive types of malignant brain tumors is glioblastoma multiforme (GBM), known for its particularly grim outlook, with an average survival time of just 12 to 15 months after diagnosis, even with aggressive treatment. Other malignant tumors, like anaplastic astrocytomas and medulloblastomas, also present significant hurdles in treatment. On the other hand, benign tumors such as meningiomas and pituitary adenomas, while not cancerous, can still lead to serious issues depending on their size and location, potentially causing neurological problems. Brain tumors interfere with normal brain function by putting pressure on nearby tissues, disrupting the flow of neural signals, and causing swelling or inflammation. Since the brain governs essential bodily functions like movement, thinking, and sensory perception, even small tumors can lead to debilitating symptoms.

The severity and type of these symptoms largely depend on the tumor's size, growth rate, and location. The effects of brain tumors on patients are deep and complex, touching not just their physical health but also their emotional, cognitive, and social lives. Many experience neurological symptoms like ongoing headaches, seizures, nausea, vomiting, and vision problems. Cognitive issues are a significant worry too, as tumors in specific areas of the brain can cause memory loss, trouble focusing, and confusion. Patients may also struggle with language and speech, motor skills, and even changes in personality, which can make it really tough to carry on with everyday activities.

The emotional weight of a brain tumor diagnosis is incredibly heavy. Patients often find themselves grappling with anxiety, depression, and emotional turmoil as they deal with the unpredictability of their condition and the side effects of treatment. The aggressive nature of many brain tumors, especially glioblastomas, doesn't leave much room for hope, which is why emotional and psychological support becomes such an essential part of their care. Families and caregivers also bear a huge burden, stepping up to provide both physical and emotional support while managing their own feelings about their loved one's diagnosis and potential decline.

On top of all this, brain tumors bring significant financial and social hurdles for patients and their families. The costs associated with treatment—like surgery, radiation, chemotherapy, and targeted therapies—can be staggering. Many patients need long-term rehabilitation, occupational therapy, and palliative care, which only adds to the financial strain. Plus, the impact on employment can be drastic, as cognitive and physical challenges might prevent individuals from continuing to work, leading to lost income and increased reliance on caregivers. Treating brain tumors is a complicated process that usually requires a mix of surgery, radiation, and chemotherapy. Surgery is often the first step, but sometimes doctors can't remove the entire tumor because of where it's located or how aggressive it is. Radiation therapy

plays a crucial role in keeping the tumor in check, while chemotherapy drugs like temozolomide can help slow down the disease.

However, one of the biggest hurdles is the blood-brain barrier, which makes it tough for many medications to work effectively. Because of this, researchers and healthcare professionals are constantly looking for new treatment options, such as immunotherapy, targeted molecular therapies, and innovative drug delivery techniques. For patients, one of the biggest worries is how both the tumor and its treatment will affect their quality of life in the long run. Many survivors face ongoing side effects like fatigue, cognitive issues, and motor difficulties. That's why rehabilitation programs are so important—they help patients regain lost abilities and boost their independence. Institutions like Duke University are dedicated to holistic patient care, offering a blend of physical therapy, speech therapy, and psychological support to ensure patients get well-rounded assistance. In recent years, the field of neuro-oncology has made significant strides, bringing hope for better survival rates and improved quality of life for those battling brain tumors. The rise of personalized medicine, which tailors treatments based on the genetic and molecular makeup of tumors, has opened doors to more targeted therapies that spare healthy brain tissue.

Clinical trials exploring immunotherapies, including oncolytic viruses and checkpoint inhibitors, are showing promise for future treatments. Plus, the integration of artificial intelligence (AI) and machine learning into diagnostics and treatment planning is helping doctors identify tumors more accurately and predict how patients will respond to different therapies. Despite the strides we've made, brain tumors still pose one of the toughest challenges in oncology. The high recurrence rates of aggressive tumors like glioblastoma, along with the limitations of existing treatments, highlight the urgent need for ongoing research and innovation. Institutions like Duke University are pouring significant resources into enhancing brain tumor therapies, aiming to boost survival rates while keeping patient well-being at the forefront.

In summary, brain tumors can have a devastating effect on patients, impacting their physical, cognitive, and emotional health, and also leading to social and financial strains. The intricate nature of brain tumors calls for a collaborative treatment approach that combines surgery, radiation, chemotherapy, and supportive care. While we've made notable progress in improving survival rates, there's still a long way to go in discovering more effective and less invasive treatment options. The continuous research and advancements in precision medicine, immunotherapy, and supportive care offer hope for a future where brain tumor patients can enjoy longer lives and a better quality of life.

2. Duke University's Role in Pioneering Research and Medical Innovations

Duke University has established itself as a powerhouse in neuro-oncology, driving groundbreaking research and medical innovations that have reshaped the landscape of brain tumor treatment. Through a multidisciplinary approach that integrates cutting-edge technology, clinical trials, and precision medicine, Duke has made significant strides in improving survival rates and the quality of life for patients battling brain tumors. One of Duke's most notable achievements is its leadership in immunotherapy, particularly with the development of PVSRIPO, a poliovirus-based treatment for glioblastoma. This groundbreaking therapy harnesses the immune system to target and destroy tumor cells, marking a major advancement in cancer treatment. The success of PVSRIPO in clinical trials has set new standards for innovative, immune-based cancer therapies, bringing hope to patients with aggressive brain tumors. Beyond immunotherapy, Duke has spearheaded advancements in precision medicine by identifying genetic and molecular markers unique to brain tumors. By leveraging this knowledge, researchers have developed targeted therapies like bevacizumab (Avastin), which inhibits tumor blood supply, improving treatment outcomes while minimizing side effects.

These personalized approaches have revolutionized brain tumor care, offering more effective and less toxic treatment options. Duke has also transformed neurosurgical techniques with state-of-the-art intraoperative imaging, navigation systems, and awake brain surgery, allowing for safer and more precise tumor removals. Additionally, innovations like convection-enhanced drug delivery (CED) have enabled direct chemotherapy administration to tumors, overcoming the limitations of the blood-brain barrier and improving drug efficacy.

The Preston Robert Tisch Brain Tumor Center at Duke stands as a global leader in research, driving forward clinical trials exploring new drug combinations, radiation strategies, and next-generation immunotherapies like CAR T-cell therapy. AI and machine learning further enhance Duke's capabilities, enabling faster, more accurate diagnoses and personalized treatment strategies based on tumor growth patterns and therapy response predictions.Beyond medical interventions, Duke prioritizes patient well-being with comprehensive rehabilitation programs, cognitive therapy, and palliative care initiatives. These efforts ensure that patients not only receive cutting-edge treatments but also have access to holistic support systems that enhance their quality of life. By combining pioneering research, innovative

treatment strategies, and compassionate patient care, Duke University continues to redefine what is possible in brain tumor treatment, setting new benchmarks in neuro-oncology and offering hope to patients worldwide. Duke University has truly been a leader in medical breakthroughs, especially in the realm of neuro-oncology.

Their pioneering research and innovative treatments have made a real difference for patients battling brain tumors. By taking a multidisciplinary approach that blends state-of-the-art technology, clinical trials, and personalized medicine, Duke has significantly advanced our understanding of brain tumors and created new therapies that boost survival rates and improve quality of life. Their contributions cover a wide array of innovations, from immunotherapy and surgical techniques to targeted therapies and AI-driven diagnostics. One of the standout achievements from Duke in the fight against brain tumors is their remarkable work in immunotherapy. A significant breakthrough came with the creation of a poliovirus-based therapy called PVSRIPO, which is an experimental treatment aimed at using the immune system to combat glioblastoma. The researchers at Duke developed a modified version of the poliovirus that specifically targets and infects tumor cells while leaving healthy tissue unharmed. This treatment, which has undergone clinical trials, has shown encouraging results by triggering an immune response that not only eliminates tumor cells but also trains the immune system to identify and attack any lingering cancerous cells. The success of PVSRIPO brought Duke into the national spotlight, as patients with previously untreatable glioblastomas experienced survival rates that exceeded all expectations.

Duke has really taken the lead in the world of innovation, especially when it comes to precision medicine and molecular-targeted therapies. For a long time, traditional chemotherapy has been the go-to treatment for brain tumors, but it often struggles to be effective due to the blood-brain barrier, which keeps many drugs from getting to the tumor. To tackle this issue, researchers at Duke have been busy pinpointing genetic and molecular markers that are unique to brain tumors. This work has paved the way for personalized treatments that are tailored to the specific characteristics of each patient's cancer. By diving into a tumor's genetic profile, doctors at Duke can figure out the best targeted therapy, which helps reduce the chances of resistance and cuts down on harmful side effects. This innovative approach has led to the successful use of drugs like bevacizumab (Avastin), which works by blocking the growth of blood vessels that supply nutrients to tumors, effectively starving them and slowing their growth.

Duke has also made impressive progress in enhancing surgical techniques and imaging technology to improve brain tumor treatment. Neurosurgeons at Duke use cutting-edge intraoperative imaging and navigation systems that allow for more precise tumor removals while keeping surrounding healthy tissue intact. The practice of awake brain surgery, where patients stay conscious during the operation, has given surgeons the ability to monitor and protect vital functions like speech and motor skills, resulting in better outcomes after surgery. Plus, Duke is leading the charge in using convection-enhanced drug delivery (CED), a technique that bypasses the blood-brain barrier by delivering chemotherapy drugs straight into the tumor through implanted catheters. This method ensures that a higher concentration of the drug reaches the tumor while minimizing the overall toxicity to the body.

Duke University isn't just about direct treatments; it's also making waves in neuro-oncology research and clinical trials. The Preston Robert Tisch Brain Tumor Center at Duke stands out as one of the top places in the world for brain cancer research. They're constantly running trials that look into new drugs, radiation methods, and combination therapies. One particularly interesting trial explored how combining checkpoint inhibitors with standard glioblastoma treatments could boost the immune system's ability to spot and attack tumors. Another groundbreaking trial examined chimeric antigen receptor (CAR) T-cell therapy, which is a type of immunotherapy that tweaks a patient's own T-cells to better identify and combat tumor cells. These research initiatives are paving the way for more effective treatments down the line. But Duke's influence goes beyond just medical interventions. They've made significant strides in enhancing the quality of life for patients through rehabilitation programs, palliative care, and survivorship initiatives.

Patients dealing with brain tumors often face cognitive challenges, motor issues, and emotional struggles that can really impact their everyday lives. To tackle this, Duke has rolled out comprehensive cognitive rehabilitation programs designed to help patients regain lost skills and adapt to new hurdles. These programs blend physical therapy, occupational therapy, and psychological support, ensuring that patients receive well-rounded care. Plus, Duke has been at the forefront of palliative care research, working on strategies that improve symptom management and provide compassionate end-of-life care for those battling terminal brain cancers. Duke University is making waves by incorporating artificial intelligence (AI) and machine learning into its research, truly transforming the landscape of brain tumor diagnosis and treatment planning. With AI-driven imaging analysis, tumors can be detected more quickly and accurately, enabling doctors to make timely and well-informed decisions about treatment options. The researchers at Duke have crafted AI algorithms that can predict how tumors will grow and how they might respond to treatments, paving the way for a more tailored approach to patient care.

By harnessing these cutting-edge technologies, Duke is at the forefront of medical innovation, setting new benchmarks in neuro-oncology. Beyond its groundbreaking research and clinical advancements, Duke is also dedicated to educating and training the next generation of neurosurgeons, oncologists, and researchers. The university's residency and fellowship programs draw in some of the brightest minds in the field, ensuring that future medical professionals are well-prepared with the knowledge and skills needed to keep advancing brain tumor treatment. Duke's collaborative spirit encourages partnerships with other top institutions, pharmaceutical companies, and government agencies, which helps speed up discoveries and brings new treatments to patients more swiftly. One of the most striking examples of Duke's influence can be seen through real patient stories.

Many individuals who faced bleak prospects after a glioblastoma diagnosis have found renewed hope and improved quality of life thanks to Duke's pioneering treatments. Some patients involved in clinical trials for PVSRIPO have outlived the usual expectations, showcasing the tangible success of Duke's research. These personal accounts highlight the institution's unwavering commitment to redefining what's possible in the realm of brain tumor treatment.

3. Innovations in Treatment Approaches

Brain tumor treatment is really moving forward at an incredible pace, thanks to exciting breakthroughs in immunotherapy, precision medicine, and advancements in surgical and radiation techniques. These new developments are changing the way we approach treatment, providing patients with more effective and personalized options that can enhance both survival rates and overall quality of life. One of the most exciting frontiers in brain tumor treatment is immunotherapy, which harnesses the power of the body's immune system to identify and attack cancer cells. Unlike traditional methods like chemotherapy and radiation that target all rapidly dividing cells, immunotherapy aims to boost the immune response in a more targeted and lasting way. A particularly intriguing strategy involves using the poliovirus as a treatment tool, which has shown promising results in tackling aggressive brain tumors such as glioblastomas. By tweaking the poliovirus to specifically target cancer cells while sparing healthy brain tissue, researchers have created a therapy that not only infects tumor cells but also sparks an immune response against them.

Clinical trials have yielded encouraging outcomes, with some patients enjoying extended survival and tumor shrinkage, underscoring the potential of viral-based immunotherapies in cancer treatment. When it comes to advancements in immunotherapy, personalized cancer vaccines are making waves beyond just viral-based methods. Unlike traditional vaccines that aim to prevent diseases, these innovative vaccines are crafted to tackle existing cancers by training the immune system to spot and attack tumor-specific antigens. By delving into the molecular makeup of a person's tumor, researchers can create highly tailored vaccines that enhance the body's ability to combat cancer. This approach not only sharpens the focus of treatment but also minimizes the harmful side effects often seen with more generalized methods. Ongoing studies are continuously fine-tuning vaccine technology, making strides in effectively targeting even the toughest tumors. On another front, precision medicine is revolutionizing the treatment of brain tumors. Instead of relying on a one-size-fits-all treatment plan, which often overlooks the unique genetic and molecular traits of each tumor, this approach incorporates genetic profiling into clinical practice.

This allows doctors to pinpoint specific mutations that fuel tumor growth and choose therapies that directly address those issues. As a result, the chances of successful treatment increase while patients avoid unnecessary exposure to ineffective medications. A standout application of precision medicine in brain tumor care is the use of targeted drug therapies, which are specifically designed to disrupt the molecular pathways that drive tumor growth. For instance, small-molecule inhibitors have been created to block the activity of mutated proteins that help cancer cells survive and multiply. Likewise, monoclonal antibodies can be tailored to bind to specific receptors on tumor cells, signaling the immune system to eliminate them. These targeted therapies have shown encouraging results in clinical trials, leading to longer survival rates and a better quality of life for patients. The way surgical techniques have evolved has played a huge role in improving brain tumor treatment, making surgeries not only safer but also more effective.

Traditional brain surgery comes with significant risks, mainly because of the brain's complex and delicate structure. Thankfully, modern neurosurgical methods now use real-time imaging, robotic assistance, and minimally invasive techniques to boost precision and cut down recovery times. For example, image-guided surgery helps surgeons navigate the brain with much greater accuracy, allowing them to remove tumors while keeping healthy tissue intact. Robotic-assisted surgeries take this a step further by stabilizing instruments and giving surgeons finer control during delicate procedures. Plus, minimally invasive options like laser ablation let surgeons target tumors through tiny incisions, which helps reduce complications after surgery and shortens hospital stays. These advancements are especially helpful for patients with tumors in hard-to-reach areas, where traditional surgery could be too risky.

Radiation therapy has come a long way, bringing with it a host of more targeted and effective treatment options. In the past, traditional radiation therapy often meant exposing large swathes of the brain to radiation, which could result in unwanted damage and long-term cognitive issues. Thankfully, newer methods like stereotactic radiosurgery and proton beam therapy are changing the game by delivering highly focused radiation directly to tumor sites while protecting healthy tissue. Despite its complex name, stereotactic radiosurgery is actually a non-invasive procedure that uses precisely aimed beams of radiation to eliminate tumors with incredible accuracy. This approach is especially beneficial for treating brain tumors that can't be surgically removed or those that come back after treatment, offering a solid alternative to traditional surgery.

On the flip side, proton beam therapy uses charged particles to deliver radiation with remarkable precision, minimizing exposure to healthy brain areas and reducing the chances of side effects. Thanks to these advancements, radiation therapy has become a more effective and safer choice for many patients, especially those who might not be ideal candidates for surgery. The blend of these groundbreaking methods is truly changing the game in brain tumor treatment, bringing fresh hope to patients who once felt they had few options. Immunotherapy is a game-changer, tapping into the immune system's potential to create long-lasting and highly targeted treatments. Meanwhile, precision medicine is customizing therapies based on the unique genetic makeup of each tumor, which boosts the effectiveness of treatments while reducing unnecessary side effects. Plus, advancements in surgical and radiation techniques are making procedures safer and more precise, enabling doctors to tackle tumors with unprecedented accuracy.

However, despite these incredible strides, there are still hurdles to overcome for these innovative treatments to become mainstream. Many of these therapies are still in the clinical trial stage and need more research to confirm their long-term effectiveness and safety. On top of that, access to these cutting-edge treatments can be hampered by financial limitations and availability, as some of the most advanced options aren't widely accessible just yet. Ongoing investment in research and healthcare infrastructure is essential to ensure that these breakthroughs can reach a larger group of patients. As science and technology keep advancing, the outlook for brain tumor treatment is looking brighter than ever. By incorporating artificial intelligence and machine learning into diagnostics and treatment planning, we can boost precision, enabling doctors to better predict how patients will respond to treatments and tailor interventions to fit individual needs. Plus, ongoing research into innovative drug combinations, gene therapies, and treatments using nanotechnology is set to broaden the spectrum of options available, making brain tumor management more effective than it has ever been.

4. Clinical Trials and Research Initiatives

Ongoing clinical trials and research initiatives are making significant strides in the fight against brain tumors, bringing fresh hope to patients with innovative therapies and groundbreaking discoveries. These clinical trials are essential for assessing new treatment methods, checking their safety, effectiveness, and potential for broader application. The involvement of patients is crucial in these trials, as real-world data from a variety of groups helps researchers fine-tune therapies and create new solutions for aggressive and treatment-resistant tumors. Many of these trials are centered around novel drug therapies, immunotherapy techniques, and combination treatments designed to enhance survival rates and improve quality of life. Given the growing complexity of brain tumors and their knack for dodging traditional treatments, clinical trials are key to expanding the horizons of what's achievable in oncology. The progress in clinical research hinges on extensive collaboration among institutions, pharmaceutical companies, and government agencies. Support from organizations like the National Cancer Institute, private foundations, and global research consortia is vital for developing new treatments and ensuring that trials can be conducted on a large scale.

The teamwork between scientists, clinicians, and data analysts has deepened our understanding of the genetic and molecular mechanisms behind brain tumors, paving the way for targeted therapies and precision medicine approaches. Additionally, international partnerships have been instrumental in speeding up research, enabling experts from various countries to exchange knowledge, resources, and patient data. These collaborative efforts not only foster innovation but also ensure that new treatments can transition from the lab to clinical practice as smoothly as possible. Duke University stands out as a leader in brain tumor research, making significant strides in setting new treatment standards. Renowned for its innovative work in neuro-oncology, Duke has been at the cutting edge of developing new therapies, such as utilizing the poliovirus in cancer treatment. At the Preston Robert Tisch Brain Tumor Center, researchers have been trailblazers in finding ways to leverage the immune system to combat glioblastomas, which are known for being particularly aggressive.

The university's commitment to clinical trials and patient-focused research has resulted in major advancements that are influencing treatment protocols around the globe. In addition to immunotherapy, Duke has played a key role in enhancing surgical techniques, refining radiation therapy methods, and advancing precision medicine strategies that

provide more targeted and effective options for brain tumor patients. As the field of brain tumor research continues to progress, clinical trials and collaborative efforts are essential for developing new therapies. The use of artificial intelligence and big data in research is enabling scientists to spot patterns in treatment responses, speeding up drug discovery, and improving clinical trial designs. Moreover, ongoing initiatives to boost patient participation in trials are making new treatments more accessible to a wider range of populations, ensuring that the results are relevant across various demographics. With ongoing investment and collaboration, the future of brain tumor treatment is looking brighter, opening up new possibilities for better survival rates and improved quality of life for patients around the world.

5. Enhancing Quality of Life for Patients

As we see advancements in brain tumor treatments, there's a growing focus on enhancing the overall well-being of patients. It's not just about the medical side of things; improving quality of life is a key part of care, ensuring that patients get the comprehensive support they need throughout their journey. Supportive care programs and rehabilitation services are crucial in helping individuals bounce back from the effects of treatments like surgery, radiation, and chemotherapy. These programs aim to boost mobility, cognitive function, and overall physical health through specialized therapies, including physical, occupational, and speech therapy. Many patients face neurological challenges after treatment, such as issues with balance, memory, or speech, which makes rehabilitation a vital aspect of long-term care. By using personalized rehabilitation strategies, healthcare providers can assist patients in regaining their independence and adjusting to changes in their daily lives but it’s not just about physical recovery; psychological and emotional well-being is equally important in patient care.

A brain tumor diagnosis can be a lot to handle, not just for patients but for their families too. Psychological support initiatives, like counseling, support groups, and mindfulness-based therapies, provide a structured way for individuals to navigate the emotional hurdles that come with their condition. Many hospitals and cancer centers offer mental health services to help patients deal with anxiety, depression, and the uncertainties of living with a brain tumor. Having access to support networks, whether in-person or online, fosters a sense of community and connection, allowing patients and caregivers to share their experiences and find comfort in knowing they’re not alone. Programs that incorporate holistic approaches, such as art therapy, meditation, and stress management techniques, are also showing promise in boosting emotional resilience and overall quality of life. For patients dealing with advanced or recurrent brain tumors, palliative care and symptom management play a crucial role in ensuring comfort and dignity. This type of care is all about easing pain, minimizing the side effects of treatment, and enhancing overall well-being, no matter what stage the disease is at. A dedicated team made up of doctors, nurses, and pain management experts collaborates closely with patients to tackle symptoms like headaches, seizures, fatigue, and cognitive changes.

By effectively managing these symptoms, we can help patients enjoy the best quality of life possible, whether they are continuing treatment or transitioning to end-of-life care. Plus, hospice services offer compassionate support for both patients and their families, guiding them through tough decisions and making sure that the care they receive aligns with their values and preferences. As we continue to emphasize patient-centered care, the combination of supportive services, mental health initiatives, and palliative care is reshaping the experience of living with a brain tumor. By addressing both the physical and emotional challenges of the disease, healthcare providers are adopting a more holistic approach to treatment, which helps patients maintain their dignity, comfort, and a sense of control over their journey. Looking ahead, it's vital that we invest in research and quality-of-life programs to ensure that brain tumor care goes beyond just survival, putting the well-being of patients front and center at every stage.

6. Future Directions and Ongoing Research

The future of treating brain tumors is being transformed by innovative research and a relentless quest for better therapies. Scientists and doctors are diving into new treatment options that push past the current standards, zeroing in on emerging therapies that could boost survival rates while reducing side effects. Cutting-edge approaches like novel drug therapies, next-gen immunotherapies, and gene-editing technologies are being explored in both clinical and lab environments. Researchers are working on new small-molecule inhibitors that specifically target mutations fueling tumor growth, along

with advanced immunotherapies aimed at enhancing the body’s ability to spot and eliminate cancer cells. On top of that, gene therapy and CRISPR technologies are under investigation for their potential to fix genetic issues tied to tumor development, paving the way for long-term disease management. As these experimental treatments move through clinical trials, they could completely change how we approach brain tumor care in the future. As new therapies are being

developed, making advanced treatments more accessible is a key priority for the medical community. Unfortunately, many groundbreaking options—like personalized cancer vaccines, targeted therapies, and proton beam radiation—are still out of reach for a large number of people due to financial, geographic, and systemic hurdles. To tackle this issue, there are ongoing efforts to improve access to these therapies through policy reforms, broader insurance coverage, and the creation of specialized treatment centers in areas that need them most. Additionally, telemedicine and digital health initiatives are helping to close the gap by enabling patients to get expert consultations and join clinical trials without having to travel long distances. With more research institutions and hospitals working together to create efficient treatment strategies, the aim is to make sure that all patients, no matter where they live or their financial circumstances, can access the best therapies available.

Duke University is leading the charge in revolutionizing brain tumor treatment, thanks to its unwavering dedication to groundbreaking research and enhancing patient outcomes. With a strong focus on innovation, Duke is at the forefront of exploring new therapeutic approaches, including exciting drug combinations, advancements in precision medicine, and cutting-edge immunotherapies. The researchers at Duke are not just aiming to extend survival rates; they're also committed to improving the quality of life for patients undergoing treatment. By harnessing the power of emerging technologies like AI-driven diagnostics and machine learning for treatment optimization, Duke is working to tailor therapies with greater precision and efficiency. Moreover, the university is passionate about a multidisciplinary approach to brain tumor care, ensuring that patients receive a well-rounded and comprehensive treatment plan. As research progresses, Duke's long-term vision is not only to boost survival rates but also to lessen the physical and cognitive challenges that come with brain tumor treatments, ultimately reshaping the standard of care for future generations. With the ongoing strides in medical science, the future of brain tumor treatment looks increasingly bright. The continuous development of new therapies, along with efforts to broaden access to advanced care, will be vital in shaping patient outcomes. As institutions like Duke University push the envelope with innovative research and treatment strategies, the next decade is poised to unveil transformative breakthroughs that will change how brain tumors are diagnosed, treated, and managed.

7. Conclusion

The strides we've made in treating brain tumors owe a lot to the innovative research and dedication to progress at Duke University. With groundbreaking therapies like immunotherapy, precision medicine, and state-of-the-art surgical techniques, Duke has been instrumental in raising the bar for treatment standards. Their work in clinical trials, teamwork in research, and focus on patient-centered care have all contributed to better survival rates and an improved quality of life for those diagnosed with brain tumors. By constantly pushing the limits of scientific exploration, Duke has established itself as a frontrunner in neuro-oncology, bringing hope to patients battling some of the toughest forms of cancer.

However, even with these advancements, treating brain tumors is still a complicated and ever-changing field, highlighting the ongoing need for research and innovation. It's crucial to keep investing in new therapies, genetic studies, and advanced treatment options to tackle the challenges posed by current methods. Making these breakthroughs accessible to more patients, no matter where they live or their financial situation, is vital. The future of brain tumor care will be shaped by collaborative research, increased funding, and patient involvement in clinical trials, paving the way for more effective and less invasive treatment options. Looking ahead, there's a lot of hope for brain tumor patients. The fast-paced advancements in science, along with the hard work of institutions like Duke, are ushering in a new era of therapies that are more personalized, targeted, and effective. As research keeps revealing new treatment options, patients and their families can hold onto optimism for longer survival, a better quality of life, and, ultimately, a cure. Thanks to innovation, teamwork, and a focus on patient-centered care, the battle against brain tumors is making real progress, bringing fresh hope to those impacted by this tough disease.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Randazzo, D. M., McSherry, F., Herndon, J. E., Affronti, M. L., Lipp, E. S., Miller, E. S., ... & Peters, K. B. (2021). Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. Neuro-Oncology Practice, 8(3), 299-309.

[2] Bonner, M. J., Hardy, K. K., Willard, V. W., Anthony, K. K., Hood, M., & Gururangan, S. (2008). Social functioning and facial expression recognition in survivors of pediatric brain tumors. Journal of pediatric psychology, 33(10), 1142-1152.

[3] Wu, A., Colón, G. R., & Lim, M. (2022). Quality of life and role of palliative and supportive care for patients with brain metastases and caregivers: a review. Frontiers in neurology, 13, 806344.

[4] Phillips, N. S., Duke, E. S., Schofield, H. L. T., & Ullrich, N. J. (2021). Neurotoxic effects of childhood cancer therapy and its potential neurocognitive impact. Journal of Clinical Oncology, 39(16), 1752.

[5] Ediebah, D. E., Quinten, C., Coens, C., Ringash, J., Dancey, J., Zikos, E., ... & Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer. (2018). Quality of life as a prognostic indicator of survival: a pooled analysis of individual patient data from Canadian cancer trials group clinical trials. Cancer, 124(16), 3409-3416.

[6] Kavanaugh, A., Gottlieb, A., Morita, A., Merola, J. F., Lin, C. Y., Birt, J., ... & Thaçi, D. (2019). The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Annals of the rheumatic diseases, 78(9), 1215-1219.

[7] Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020). Management of glioblastoma: State of the art and future directions. CA: a cancer journal for clinicians, 70(4), 299-312.

[8] Leonetti, A., Puglisi, G., Rossi, M., Viganò, L., Conti Nibali, M., Gay, L., ... & Bello, L. (2021). Factors influencing mood disorders and health related quality of life in adults with glioma: a longitudinal study. Frontiers in oncology, 11, 662039.

[9] Czech, O., Rutkowski, S., Kowaluk, A., Kiper, P., & Malicka, I. (2023). Virtual reality in chemotherapy support for the treatment of physical functions, fear, and quality of life in pediatric cancer patients: A systematic review and meta-analysis. Frontiers in Public Health, 11, 1039720.

[10] Peters, K. B., Affronti, M. L., Woodring, S., Lipp, E., Healy, P., Herndon, J. E., ... & Friedman, H. S. (2022). Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. Supportive Care in Cancer, 1-9.

[11] Mark, D. B., Anstrom, K. J., Sheng, S., Piccini, J. P., Baloch, K. N., Monahan, K. H., ... & CABANA Investigators. (2019). Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. Jama, 321(13), 1275-1285.

[12] Sheehan, J. P., Grills, I., Chiang, V. L., Dong, H., Berg, A., Warnick, R. E., ... & Kavanagh, B. (2018). Quality of life outcomes for brain metastasis patients treated with stereotactic radiosurgery: pre-proc

[13] Thierheimer, M., Cioffi, G., Waite, K. A., Kruchko, C., Ostrom, Q. T., & Barnholtz-Sloan, J. S. (2023). Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex. Journal of Neuro-oncology, 162(1), 167-177.

[14] Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022). CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro-oncology, 24(Supplement_5), v1-v95.

[15] Trivedi, R., Man, H., Madut, A., Mather, M., Elder, E., Dhillon, H. M., ... & Kairaitis, K. (2021). Irregular sleep/wake patterns are associated with reduced quality of life in post-treatment cancer patients: a study across three cancer cohorts. Frontiers in Neuroscience, 15, 700923.

[16] Kim, M. M., Mehta, M. P., Smart, D. K., Steeg, P. S., Hong, J. A., Espey, M. G., ... & Ahmed, M. M. (2023). National cancer institute collaborative workshop on shaping the landscape of brain metastases research: challenges and recommended priorities. The Lancet Oncology, 24(8), e344-e354.

[17] Crawford, J., Herndon, D., Gmitter, K., & Weiss, J. (2024). The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncology, 20(21), 1515-1530.

[18] Gounder, M., Ratan, R., Alcindor, T., Schöffski, P., Van Der Graaf, W. T., Wilky, B. A., ... & Kasper, B. (2023). Nirogacestat, a γ-secretase inhibitor for desmoid tumors. New England Journal of Medicine, 388(10), 898-912.

[19] Plant-Fox, A. S., O'Halloran, K., & Goldman, S. (2021). Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Current Problems in Cancer, 45(4), 100777.

[20] Shah, P. P., White, T., Khalafallah, A. M., Romo, C. G., Price, C., & Mukherjee, D. (2020). A systematic review of tumor treating fields therapy for high-grade gliomas. Journal of neuro-oncology, 148, 433-443.

[21] Ajlouni, N., Özyavaş, A., Ajlouni, F., Takaoğlu, M., & Takaoğlu, F. (2024). Enhancing TNM Staging in Breast Cancer: A Hybrid Approach with CNN, Edge Detection, and Self-Organizing Maps for Improved Accuracy.

[22] Kang, J. H., Swisher, C. B., Buckley, E. D., Herndon, J. E., Lipp, E. S., Kirkpatrick, J. P., ... & Peters, K. B. (2021). Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. CNS oncology, 10(3), CNS77.

[23] Mondia, M. W. L., Espiritu, A. I., & Jamora, R. D. G. (2020). Primary brain tumor research productivity in Southeast Asia and its association with socioeconomic determinants and burden of disease. Frontiers in Oncology, 10, 607777.

[24] Leak Bryant, A., Reeve, B. B., Gosselin, T., Coffman, E. M., Phillips, B., Gray, T. F., ... & Muss, H. (2018, September). Symptoms, Mobility and Function, and Quality of Life in Adults With Acute Leukemia During Initial Hospitalization. In Oncology nursing forum (Vol. 45, No. 5).

[25] Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J. S., Zou, X., ... & He, J. (2018). Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health, 6(5), e555-e567.